G-CAN endorsed labels and definitions for the disease states of gout
| Consensus label | Consensus definition | |
| Pre-clinical states | 1. Asymptomatic hyperuricaemia* | Hyperuricaemia* in the absence of gout. |
| 2. Asymptomatic MSU crystal deposition | Evidence of MSU crystal deposition in the absence of gout. MSU crystal deposition may be demonstrated by imaging or microscopic analysis | |
| 3. Asymptomatic hyperuricaemia* with MSU crystal deposition | Hyperuricaemia* with evidence of MSU crystal deposition in the absence of gout. MSU crystal deposition may be demonstrated by imaging or microscopic analysis | |
| Clinical states | 4. Gout | A disease caused by MSU crystal deposition with any of the following clinical presentations (current or prior): gout flare, chronic gouty arthritis, or subcutaneous tophus |
| 5. Tophaceous gout | Gout with at least one subcutaneous tophus | |
| 6. Erosive gout | Gout with at least one gouty bone erosion | |
| Disease course states | 7. First gout flare | The first episode of gout flare |
| 8. Recurrent gout flares | More than one gout flare | |
| Additional recommendation on disease states not addressed by the nomenclature | Where there is more than one disease state present, these can be combined (eg, tophaceous and erosive gout). Where there are additional elements present, not recognised as disease states, these will be labelled as the recognised disease state with or without additional disease elements (eg, tophaceous gout with chronic gouty arthritis) | |
*In British English, hyperuricaemia.
MSU, monosodium urate.